Are there specific immunotherapy drugs that synergize with lurbinectedin?

Lurbinectedin works by binding DNA minor grooves and inhibiting transcription in cancer cells. It shows activity against small cell lung cancer and other solid tumors.

Why do researchers test lurbinectedin with immunotherapy?

Researchers combine lurbinectedin with checkpoint inhibitors to turn cold tumors into hot tumors. Cold tumors contain few immune cells. Turning them into hot ones brings immune cells inside. Lurbinectedin releases tumor antigens and depletes myeloid-derived suppressor cells, helping the checkpoint inhibitor work.

What happens if lurbinectedin is combined with atezolizumab?

A phase Ib/II study tested lurbinectedin plus atezolizumab in relapsed extensive-stage small cell lung cancer. The combination showed manageable safety and durable responses. Some patients stayed progression-free beyond 18 months.

What happens when lurbinectedin is combined with pembrolizumab?

A separate study tested lurbinectedin plus pembrolizumab in multiple tumor types. The combination showed acceptable safety and promising early activity. Data from this study remain limited to phase I/II levels.

Are there ongoing trials exploring further combinations?

Yes. Ongoing trials include lurbinectedin plus durvalumab in thoracic malignancies and lurbinectedin plus nivolumab in soft tissue sarcoma. The trials cover different tumor types and stage settings.

How does this combination approach affect patents?

Lurbinectedin holds composition-of-matter protection until 2035 in the US. Check patents covering combination uses separately. Visit https://www.drugpatentwatch.com for latest updates.

How does this combination approach affect pricing?

Pricing for lurbinectedin alone remains at premium levels. Premix kits of lurbinectedin and an checkpoint inhibitor will likely stay premium priced until competition arrives.